WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Mary MillerChief Legal Officer2025-04-17558$1.81
$1.01kSell
Peter BlumejensenPresident and CEO2025-02-2119,904$5.54
$110.27kSell
Peter BlumejensenPresident and CEO2025-02-1437,152$5.42
$201.36kSell
Mary MillerChief Legal Officer2025-02-14217$5.42
$1.18kSell
Katharine PetersonChief Accounting Officer2025-02-14116$5.42
$628.72Sell
Peter BlumejensenPresident and CEO2025-02-14579$5.42
$3.14kSell
Rasmus HolmjorgensenChief Financial Officer2025-02-14434$5.42
$2.35kSell
Eric DevroeChief Operating Officer2025-02-14724$5.42
$3.92kSell
Erick GamelinChief Development Officer2025-02-14469$5.42
$2.54kSell
Mary MillerChief Legal Officer2025-01-17659$5.78
$3.81kSell

1 of 4

ACRV insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP26.60%8,340,508$15.93MInstitution
Perceptive Advisors LLC17.10%5,360,858$10.24MInsider
Perceptive Advisors LLC17.10%5,360,858$10.24MInstitution
Chione Ltd12.28%3,848,632$7.35MInsider
Kristina Masson11.77%3,691,232$7.05MInsider
Peter Blumejensen9.24%2,895,956$5.53MInsider
Sands Capital Ventures LLC6.77%2,122,605$4.05MInstitution
Citadel Advisors LLC6.76%2,119,646$4.05MInstitution
Blackrock Inc3.02%945,496$1.81MInstitution
Wellington Biomedical Innovation Master Investors Cayman I LP2.83%888,130$1.70MInsider

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV57.37%42.63%Net SellingNet Selling
MGX28.70%33.25%Net SellingNet Selling
VTVT0.90%99.10%Net Buying
PYXS51.20%37.91%Net Buying
GUTS47.12%52.88%Net SellingNet Buying
View Top Biotech Stocks

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 74.16% institutional shareholders, 55.10% Acrivon Therapeutics insiders, and 0.00% retail investors. Perceptive Advisors LLC is the largest individual Acrivon Therapeutics shareholder, owning 5.36M shares representing 17.10% of the company. Perceptive Advisors LLC's Acrivon Therapeutics shares are currently valued at $10.88M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.